vs
礼来（RNA）与Spero Therapeutics, Inc.（SPRO）财务数据对比。点击上方公司名可切换其他公司
Spero Therapeutics, Inc.的季度营收约是礼来的1.0倍（$12.6M vs $12.5M），Spero Therapeutics, Inc.净利率更高（250.7% vs -1398.3%，领先1649.0%），Spero Therapeutics, Inc.同比增速更快（24080.8% vs 434.0%），过去两年Spero Therapeutics, Inc.的营收复合增速更高（847.7% vs 138.5%）
礼来是总部位于美国印第安纳州印第安纳波利斯的跨国制药企业，在18个国家设有办事处，产品销往全球约125个国家。公司由美国内战时期联邦军退伍军人、药剂师伊莱·礼来于1876年创立，品牌名即取自创始人姓名。
RNA vs SPRO — 直观对比
营收规模更大
SPRO
是对方的1.0倍
$12.5M
营收增速更快
SPRO
高出23646.7%
434.0%
净利率更高
SPRO
高出1649.0%
-1398.3%
两年增速更快
SPRO
近两年复合增速
138.5%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $12.5M | $12.6M |
| 净利润 | $-174.4M | $31.5M |
| 毛利率 | — | — |
| 营业利润率 | -1513.5% | — |
| 净利率 | -1398.3% | 250.7% |
| 营收同比 | 434.0% | 24080.8% |
| 净利润同比 | -117.0% | 250.9% |
| 每股收益（稀释后） | $-1.27 | $0.56 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RNASPRO
| Q4 25 | — | $12.6M | ||
| Q3 25 | $12.5M | $0 | ||
| Q2 25 | $3.8M | $0 | ||
| Q1 25 | $1.6M | $12.0K | ||
| Q4 24 | $3.0M | $52.0K | ||
| Q3 24 | $2.3M | $65.0K | ||
| Q2 24 | $2.0M | $114.0K | ||
| Q1 24 | $3.5M | $140.0K |
净利润RNASPRO
| Q4 25 | — | $31.5M | ||
| Q3 25 | $-174.4M | $-7.4M | ||
| Q2 25 | $-157.3M | $-1.7M | ||
| Q1 25 | $-115.8M | $-13.9M | ||
| Q4 24 | $-102.3M | — | ||
| Q3 24 | $-80.4M | $-17.1M | ||
| Q2 24 | $-70.8M | $-17.9M | ||
| Q1 24 | $-68.9M | $-12.7M |
营业利润率RNASPRO
| Q4 25 | — | — | ||
| Q3 25 | -1513.5% | — | ||
| Q2 25 | -4448.7% | — | ||
| Q1 25 | -8360.9% | -122758.3% | ||
| Q4 24 | -4069.6% | — | ||
| Q3 24 | -4200.9% | -28604.6% | ||
| Q2 24 | -4040.4% | -16720.2% | ||
| Q1 24 | -2178.6% | -9987.1% |
净利率RNASPRO
| Q4 25 | — | 250.7% | ||
| Q3 25 | -1398.3% | — | ||
| Q2 25 | -4089.3% | — | ||
| Q1 25 | -7360.0% | -115550.0% | ||
| Q4 24 | -3439.5% | — | ||
| Q3 24 | -3441.7% | -26380.0% | ||
| Q2 24 | -3461.8% | -15668.4% | ||
| Q1 24 | -1943.4% | -9049.3% |
每股收益（稀释后）RNASPRO
| Q4 25 | — | $0.56 | ||
| Q3 25 | $-1.27 | $-0.13 | ||
| Q2 25 | $-1.21 | $-0.03 | ||
| Q1 25 | $-0.90 | $-0.25 | ||
| Q4 24 | $-0.80 | — | ||
| Q3 24 | $-0.65 | $-0.32 | ||
| Q2 24 | $-0.65 | $-0.33 | ||
| Q1 24 | $-0.79 | $-0.24 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $350.2M | $40.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.9B | $59.0M |
| 总资产 | $2.1B | $68.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资RNASPRO
| Q4 25 | — | $40.3M | ||
| Q3 25 | $350.2M | $48.6M | ||
| Q2 25 | $243.9M | $31.2M | ||
| Q1 25 | $254.2M | $48.9M | ||
| Q4 24 | $219.9M | $52.9M | ||
| Q3 24 | $370.2M | $76.3M | ||
| Q2 24 | $575.8M | $63.5M | ||
| Q1 24 | $471.4M | $82.3M |
股东权益RNASPRO
| Q4 25 | — | $59.0M | ||
| Q3 25 | $1.9B | $26.5M | ||
| Q2 25 | $1.2B | $32.8M | ||
| Q1 25 | $1.3B | $33.8M | ||
| Q4 24 | $1.4B | $46.1M | ||
| Q3 24 | $1.5B | $65.5M | ||
| Q2 24 | $1.2B | $80.5M | ||
| Q1 24 | $830.9M | $96.2M |
总资产RNASPRO
| Q4 25 | — | $68.9M | ||
| Q3 25 | $2.1B | $54.2M | ||
| Q2 25 | $1.4B | $62.1M | ||
| Q1 25 | $1.5B | $77.7M | ||
| Q4 24 | $1.6B | $110.5M | ||
| Q3 24 | $1.6B | $135.2M | ||
| Q2 24 | $1.3B | $149.9M | ||
| Q1 24 | $951.5M | $167.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-156.2M | $-8.4M |
| 自由现金流经营现金流 - 资本支出 | $-156.9M | — |
| 自由现金流率自由现金流/营收 | -1257.6% | — |
| 资本支出强度资本支出/营收 | 5.7% | — |
| 现金转化率经营现金流/净利润 | — | -0.26× |
| 过去12个月自由现金流最近4个季度 | $-592.3M | — |
8季度趋势，按日历期对齐
经营现金流RNASPRO
| Q4 25 | — | $-8.4M | ||
| Q3 25 | $-156.2M | $17.4M | ||
| Q2 25 | $-199.7M | $-17.7M | ||
| Q1 25 | $-124.8M | $-4.0M | ||
| Q4 24 | $-99.9M | $-23.4M | ||
| Q3 24 | $-65.6M | $12.8M | ||
| Q2 24 | $-65.0M | $-18.7M | ||
| Q1 24 | $-70.4M | $5.9M |
自由现金流RNASPRO
| Q4 25 | — | — | ||
| Q3 25 | $-156.9M | — | ||
| Q2 25 | $-203.0M | — | ||
| Q1 25 | $-128.6M | — | ||
| Q4 24 | $-103.8M | — | ||
| Q3 24 | $-67.3M | — | ||
| Q2 24 | $-65.5M | — | ||
| Q1 24 | $-71.3M | — |
自由现金流率RNASPRO
| Q4 25 | — | — | ||
| Q3 25 | -1257.6% | — | ||
| Q2 25 | -5277.1% | — | ||
| Q1 25 | -8174.3% | — | ||
| Q4 24 | -3491.0% | — | ||
| Q3 24 | -2881.8% | — | ||
| Q2 24 | -3204.6% | — | ||
| Q1 24 | -2012.3% | — |
资本支出强度RNASPRO
| Q4 25 | — | — | ||
| Q3 25 | 5.7% | — | ||
| Q2 25 | 86.9% | — | ||
| Q1 25 | 238.6% | — | ||
| Q4 24 | 131.7% | — | ||
| Q3 24 | 72.9% | — | ||
| Q2 24 | 26.0% | — | ||
| Q1 24 | 25.8% | — |
现金转化率RNASPRO
| Q4 25 | — | -0.26× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
